Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Ariela Noy, Win Su Thet, Shreya Vemuri, Venkatraman Seshan, Connie Lee Batlevi, Zachary D. Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Thomas M. Habermann, Paul A. Hamlin, Erel Joffe, Jennifer Kimberly Lue, Matthew Matasar, Maria Lia Palomba, Andrew D. Zelenetz, Gilles Salles

Blood (2024) 144 (Supplement 1): 6352.

https://doi.org/10.1182/blood-2024-211730

Published: 2024

Journal Articles

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Jacob D. Soumerai, Ahmet Dogan, Venkatraman Seshan, Kelsey Leigh Flaherty, Natalie Slupe, Jason Carter, Ephraim Hochberg, Jeffrey A. Barnes, Jeremy S. Abramson, Audrey Hamilton, Ariela Noy, Colette Owens, Maria Lia Palomba, Anita Kumar, Lindsey Roeker, Meghan C. Thompson, Ronald W. Takvorian, Zachary D. Epstein-Peterson, Mark Blaine Geyer, Gilles Salles, Robert Stuver, Philip Caron, Prioty Islam, Tamanna Haque, Paola Ghione, Raphael E. Steiner, Pallawi Torka, Kevin A. David, Jennifer Kimberly Lue, Paul A. Hamlin, Alison Moskowitz, Lorenzo Falchi, Julie Haydu, Patrick Connor Johnson, Joanna Mi, Jessica Pendleton, Alyssa Labarre, Rosalba Martignetti, Sean F. Plummer, Maria Chabowska, Walter Ramos Amador, Neena Mahajan, Morgan Choma, Clare Grieve, Rayna N. Garcia, Hailey E. Kelly, Ella Mallinger, James O'Grady, Bernadette Beatty, Michelle Adams, Athina Apazidis, Aileen Cleary Cohen, Mina Shahkarami, Allison P. Jacob, Omar Abdel-Wahab, Andrew D. Zelenetz

Blood (2024) 144 (Supplement 1): 1867.

https://doi.org/10.1182/blood-2024-205697

Published: 2024

Journal Articles

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 3053.

https://doi.org/10.1182/blood-2024-210053

Published: 2024

Journal Articles

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Blood (2024) 144 (Supplement 1): 1707.

https://doi.org/10.1182/blood-2024-194144

Published: 2024

Journal Articles

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Blood (2023) 142 (26): 2327–2331.

https://doi.org/10.1182/blood.2023021274

Published: 2023

Includes: Supplemental data

Journal Articles

Genetic Alterations of Follicular Lymphoma Can Predict Response to Very Low Dose Radiotherapy

N. Ari Wijetunga, Emily Lebow, Alexander Chan, Beatrice Fregonese, Venkatraman Seshan, Carla Hajj, Gustav Cederquist, Harper Hubbeling, Jennifer Ma, Reith R Sarkar, Kathryn Tringale, Pallavi Galera, Erel Joffe, Ahmet Dogan, Hans-Guido Wendel, Andrew D. Zelenetz, Gilles Salles, Brandon S. Imber, Joachim Yahalom

Blood (2023) 142 (Supplement 1): 6099.

https://doi.org/10.1182/blood-2023-185338

Published: 2023

Journal Articles

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 738.

https://doi.org/10.1182/blood-2023-180069

Published: 2023

Journal Articles

Real-World Outcomes in Patients with Transformed Follicular Lymphoma Treated with CD19-Targeting CAR-T Therapy

Blood (2023) 142 (Supplement 1): 4888.

https://doi.org/10.1182/blood-2023-187379

Published: 2023

Journal Articles

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3136.

https://doi.org/10.1182/blood-2023-182204

Published: 2023

Journal Articles

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

David Qualls, Michael J Buege, Phuong Dao, Paolo F. Caimi, Sarah C. Rutherford, Graham Wehmeyer, Jason T. Romancik, Lori A. Leslie, Mwanasha H. Merrill, Jennifer L. Crombie, Behzad Amoozgar, Brad S. Kahl, David A. Bond, Kami J. Maddocks, Michelle Okwali, Venkatraman Seshan, Gilles Salles, Connie Lee Batlevi

Blood (2022) 140 (Supplement 1): 787–789.

https://doi.org/10.1182/blood-2022-167620

Published: 2022

Journal Articles

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Blood (2022) 140 (Supplement 1): 9251–9253.

https://doi.org/10.1182/blood-2022-158783

Published: 2022

Journal Articles

Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma

Neil Ari Wijetunga, Emily S. Lebow, Jisun Lee, Beatrice Fregonese, Kathryn R. Tringale, Harper Hubbeling, Reith Sarkar, Jennifer Ma, Venkatraman Seshan, Erel Joffe, Ahmet Dogan, Alexander Chan, Guido Wendel, Carla Hajj, Brandon S. Imber, Joachim Yahalom

Blood (2022) 140 (Supplement 1): 6413–6414.

https://doi.org/10.1182/blood-2022-169501

Published: 2022

Journal Articles

BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas

Pallavi K Galera, David Qualls, Umut Aypar, Caroline Kostrzewa, Menglei Zhu, Jeeyeon Baik, Venkatraman Seshan, Gilles Salles, Ahmet Dogan

Blood (2022) 140 (Supplement 1): 6396–6398.

https://doi.org/10.1182/blood-2022-163849

Published: 2022

Journal Articles

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Anita Kumar, Jason R. Westin, Stephen J. Schuster, Grzegorz S. Nowakowski, Izidore S. Lossos, Devin Copley, Clare Grieve, Allison P. Jacob, Ashlee Joseph, Leana Laraque, Gita Masand, Chelsea D Mullins, Ellen Napier, Tania Rodriguez, Venkatraman Seshan, Shreya Vemuri, Andrew D. Zelenetz

Blood (2021) 138 (Supplement 1): 52.

https://doi.org/10.1182/blood-2021-150572

Published: 2021

Journal Articles

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Blood (2021) 138 (Supplement 1): 2447.

https://doi.org/10.1182/blood-2021-154226

Published: 2021

Journal Articles

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Blood (2021) 138 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2021-151831

Published: 2021

Journal Articles

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Blood (2021) 138 (Supplement 1): 3753.

https://doi.org/10.1182/blood-2021-150961

Published: 2021

Journal Articles

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

Neeta Bala Tannan, Mandana T. Manzari, Laurie Herviou, Mariana Da Silva Ferreira, Connor Hagen, Hiroto Kiguchi, Katia Manova-Todorova, Venkatraman Seshan, Elisa de Stanchina, Daniel A. Heller, Anas Younes

Blood (2021) 137 (15): 2057–2069.

https://doi.org/10.1182/blood.2020008017

Published: 2021

Includes: Supplemental data

Journal Articles

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-136438

Published: 2020

Journal Articles

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138889

Published: 2020

NARROW

Rituximab +/- Ibrutinib As First Line Therapy for Marginal Zone Lymphoma

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

Final Response and Survival Results from a Phase II Trial of Pembrolizumab and Entinostat in Relapsed/Refractory Hodgkin Lymphoma

High Grade B-Cell Lymphoma with MYC/BCL6-Rearrangements (R) May Have Inferior Outcomes Compared to BCL2-R Disease

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Genetic Alterations of Follicular Lymphoma Can Predict Response to Very Low Dose Radiotherapy

A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Patients with Treatment-Naïve, TP53 -Mutant Mantle Cell Lymphoma

Real-World Outcomes in Patients with Transformed Follicular Lymphoma Treated with CD19-Targeting CAR-T Therapy

Outcomes of Sequential CD19-Directed Therapies in Relapsed and Refractory Large B Cell Lymphoma

Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma

BCL6 Rearranged Indolent B-Cell Lymphomas Show Mutational Profile Similar to Marginal Zone Lymphomas

A Prospective Multicenter Study of Minimal Residual Disease Assessment Using a Next-Generation Immunosequencing Assay and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL)

Preliminary Safety and Efficacy from a Multicenter, Investigator-Initiated Phase II Study in Untreated TP53 Mutant Mantle Cell Lymphoma with Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen)

Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition

R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET

Interim Analysis from a Prospective Multicenter Study of Next-Generation Sequencing Minimal Residual Disease Assessment and CT Monitoring for Surveillance after Frontline Treatment in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only